Suzhou Ronnsi Pharma Co., Ltd. 

Suzhou Ronnsi Pharma Co., Ltd., (named “Ronnsi”) founded in Suzhou Industrial Park in November 2012, is a leading pharmaceutical company in China focus on complex drugs development. Our main products are sheep derived heparin, including purified ovine heparin and ovine (sheep) enoxaparin sodium. Ronnsi has world class scientific research and drug development team. 
Ronnsi has granted multiple invention patents, including ovine enoxaparin sodium and other ovine low molecular weight heparin derivatives. Ovine enoxaparin sodium has been approved by BPOM (Indonesia FDA) as a biosimilar product in April 2021. Ovine enoxaparin sodium has also been submitted to China FDA and is discussing with US FDA as 505b2 application. Ovine enoxaparin sodium is the first and also the only non-porcine low molecular weight heparin approved in the world. Working with world renewed heparin researchers, Ronnsi has published more than 10 scientific papers with high impact factor in the field of complex polysaccharide drugs.
Ronnsi's commercial stage products are innovative and patented ovine origin heparin drugs, which will serve the unmet medical needs of the Muslim people. Ronnsi is actively  collaborating with international pharmaceutical companies, and is committed to build the company into the world largest and special ovine heparin drug company.
Ronnsi’s vision is to attract top notch researchers to develop first-in-class, best-in-class and unmet medicines for patients